Smart Nanovesicle-Mediated Immunogenic Cell Death through Tumor Microenvironment Modulation for Effective Photodynamic Immunotherapy

Yang, Weijing; Zhang, Fuwu; Deng, Hongzhang; Lin, Lisen; Wang, Sheng; Kang, Fei; Yu, Guocan; Lau, Joseph; Tian, Rui; Zhang, Mingru; Wang, Zhantong; He, Liangcan; Ma, Ying; Niu, Gang; Hu, Shuo; Chen, Xiaoyuan

doi:10.1021/acsnano.9b07212

Cited by 224 publications

(170 citation statements)

References 54 publications

Supporting

Mentioning

166

Contrasting

Order By: Relevance

“…Chen's group reported pH‐responsive nanovesicles (pRNVs) encapsulated with a photosensitizer (2‐(1‐hexyloxyethyl)‐2‐devinyl pyropheophorbide‐a (HPPH)) and an IDO inhibitor (IND) for pH‐activatable immunometabolic cancer therapy ( Figure a). [ 39 ] pRNVs were self‐assembled from block copolymer polyethylene glycol (PEG)‐ b ‐cationic polypeptide, which not only served as a carrier for pH‐activated release of therapeutic agents but also induced ICD to increase the tumor immunogenicity. In vitro drug release profiles validated that both HPPH and IND could be rapidly released from pRNVs at pH 5.0 phosphate buffered saline (PBS) buffer (Figure 3b).…”

Section: Photo‐immunometabolic Therapymentioning

confidence: 99%

Recent Progress on Activatable Nanomedicines for Immunometabolic Combinational Cancer Therapy

Zhang

2020

Small Structures

View full text Add to dashboard Cite

Cancer immunotherapy that stimulates the patient's immune system to eradicate cancer cells is a revolutionary strategy for the treatment of malignancies. [1] Compared to traditional chemotherapy and radiotherapy, which kill both cancer cells and normal cells, cancer immunotherapy can activate antitumor immune response to specifically target and eliminate cancer cells. [2] In general, the generation of antitumor immune response consists of a series of immunological processes. [3] First, tumor-associated antigens (TAAs) and danger-associated molecular patterns (DAMPs) are released from dying tumor cells. [4] Then, TAAs are captured by antigen-presenting cells (APCs), and DAMPs induce the activation and maturation of APCs. Activated APCs travel to lymph nodes and present TAAs on major histocompatibility complex I (MHC I) and MHC II molecules to T cells, leading to the activation of T cells. [5] Finally, activated T cells infiltrate the tumor tissues, recognize TAA-specific tumor cells, and release effector molecules (granzyme B and perforin) to kill tumor cells. [6] Up to now, several immunotherapies (e.g., immune checkpoint blockade (ICB), adoptive cell transfer, and cancer vaccine) that focus on the initiation and activation of antitumor immunity via various targets or mechanisms have been developed and achieved some progress in preclinical research and clinical translation. [7] Immunometabolic cancer therapy is an emerging therapeutic strategy that modulates tumor metabolic signaling pathways to activate immune cells to fight against tumors (Scheme 1a). [8] The proliferation and growth of cells generally involve a network of metabolic reactions (such as glycolysis, the tricarboxylic acid cycle, and amino acid metabolism). [9] In tumor cells, the dysregulation of cellular metabolic programs (e.g., nutrient limitation, immunosuppressive metabolites, and inhibitory immunometabolic signaling pathways) can lead to the failure of the immune system to fight against the tumor. [10] Tumor metabolic programs not only reflect the cellular state, but also play essential roles to restrict antigen presentation, initiate immune suppression or exhaustion, and impair the function of immune cells (including tumor-associated macrophages (TAMs), natural killer (NK) cells, effector T (T eff) cells, and regulatory T (T reg) cells). [11] Thereby, immunometabolic therapy that targets or modulates metabolic circuits to reprogram cancer metabolism can greatly attenuate tumor progression and reinvigorate antitumor immunity. [12] For example, inhibition of lactic acid production has been utilized to reduce tumor growth and unleash antitumor immunity; blockade of glutamine catabolism can inhibit the proliferation of tumor cells and recover the function and activity of TAMs and T eff cells. [8c] Thus, the development and advancement of immunometabolic therapies holds promise to improve the effectiveness of the treatment of cancer. Despite the progress, the clinical translation of cancer immunotherapies still faces some obstacles, such as immu...

show abstract

Section: Photo‐immunometabolic Therapymentioning

confidence: 99%

Recent Progress on Activatable Nanomedicines for Immunometabolic Combinational Cancer Therapy

Zhang

2020

Small Structures

View full text Add to dashboard Cite

show abstract

“…In situ burst releases of tumor antigens induced by PDT significantly initiated the immune response (Ng et al, 2018 ; Meng et al, 2019a ; Wang et al, 2019 ). Yang et al ( 2020 ) prepared the pH-responsive double load nanovesicles (named PEG-b-cPPT) by self-assembly of block copolymer polyethylene glycol-b-cationic polypeptide. In the acidic environment, the double-loaded nanoparticles released the PS and indoximod into the cytoplasm because of the protonation of the tertiary amine in the cationic polypeptide.…”

Section: Tmrns As Targeted Delivery Carriers For Photodynamic Anticanmentioning

confidence: 99%

Tumor Microenvironment-Responsive Nanomaterials as Targeted Delivery Carriers for Photodynamic Anticancer Therapy

et al. 2020

View full text Add to dashboard Cite

Photodynamic therapy (PDT), as an alternative approach to treat tumors through reactive oxygen species (ROS) produced by the activated photosensitizers (PS) upon light irradiation, has attracted wide attention in recent years due to its low invasive and highly efficient features. However, the low hydrophilicity and poor targeting of PS limits the clinical application of PDT. Stimuli-responsive nanomaterials represent a major class of remarkable functional nanocarriers for drug delivery. In particular, tumor microenvironment-responsive nanomaterials (TMRNs) can respond to the special pathological microenvironment in tumor tissues to release the loaded drugs, that allows them to control the release of PS within tumor tissues. Recent studies have demonstrated that TMRNs can achieve the targeted release of PS at tumor sites, increase the concentration of PS in tumor tissues, and reduce side effects of PDT. Hence, in the present paper, we review TMRNs, mainly including pH-, redox-, enzymes-, and hypoxia-responsive smart nanomaterials, and focus on the application of these smart nanomaterials as targeted delivery carriers of PS in photodynamic anticancer therapy, to further boost the development of PDT in tumor therapy.

show abstract

“…This may be important because as seen in a recent study, there were no significant changes of posttreatment to pretreatment median CD8+TIL density ratio in OPC patients who received durvalumab (PD-L1 inhibitor) ordurvalumab plus tremelimumab (CTLA-4 inhibitor) [75]. Yang et al developed a nanovesicle platform which includes pH-responsive nanovesicles (pRNVs) self-assembled from block copolymer polyethylene glycol-b-cationic polypeptide (PEG-b-cPPT) [76]. These nanovesicles can encapsulate a photosensitizer and indoximod, an indoleamine 2, 3-dioxygenase inhibitor, to improve efficient drug delivery.…”

Section: Combination Therapymentioning

confidence: 99%

“…The dual combination can also induce reactive oxygen species (ROS) generation and ICD effects. Importantly, the recruitment of DCs was increased, the immune response was activated and the tumor microenvironment was modulated via indoximod with increased CD8 + T cell infiltration [76]. Other approaches such as immunotherapy combined with photothermal therapy or photodynamic therapy or gene therapy were also reported (for a detailed overview, please refer to a review by Nam et al) [77].…”

Section: Combination Therapymentioning

confidence: 99%

Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck

Fang

Zhu

et al. 2020

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Immunotherapies such as immune checkpoint blockade benefit only a portion of patients with head and neck squamous cell carcinoma. The multidisciplinary field of nanomedicine is emerging as a promising strategy to achieve maximal anti-tumor effect in cancer immunotherapy and to turn non-responders into responders. Various methods have been developed to deliver therapeutic agents that can overcome bio-barriers, improve therapeutic delivery into the tumor and lymphoid tissues and reduce adverse effects in normal tissues. Additional modification strategies also have been employed to improve targeting and boost cytotoxic T cell-based immune responses. Here, we review the state-of-the-art use of nanotechnologies in the laboratory, in advanced preclinical phases as well as those running through clinical trials assessing their advantages and challenges.

show abstract

Smart Nanovesicle-Mediated Immunogenic Cell Death through Tumor Microenvironment Modulation for Effective Photodynamic Immunotherapy

Cited by 224 publications

References 54 publications

Recent Progress on Activatable Nanomedicines for Immunometabolic Combinational Cancer Therapy

Recent Progress on Activatable Nanomedicines for Immunometabolic Combinational Cancer Therapy

Tumor Microenvironment-Responsive Nanomaterials as Targeted Delivery Carriers for Photodynamic Anticancer Therapy

Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck

Contact Info

Product

Resources

About